⌕
Neogenomics · NEO · Nasdaq
Tenet 37 · Weak
Compare
$15.25−1.04%At closeTenet 37 · Weak
$15.25−0.16 (−1.04%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Neogenomics (NEO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~10.7%/yr (FY21→FY25), net margin −14.9%. Worth your attention in FY25: Share count (+6.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲10.1%
727.3
FY21→FY25CAGR +10.7%/yr
Net income ($M)▼37.2%
−108.0
one-off year: see footnoteCAGR —
Free cash flow ($M)▲36.0%
−21.8
FY21→FY25CAGR —
Diluted EPS▼35.5%
−0.84
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+6.8%

120.0mn → 128.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$27.0M

−34.2% YoY in FY25 · 3.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)727.3Revenue−413.0COGS314.3Gross profit−37.1R&D−273.3SG&A−115.9Op income7.9Tax & other−108.0Net income

-15¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
503825130%sector median net margin ~3%FY21FY25

Over this window: gross 38.6% → 43.2%. Net margin -14.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
787.8727.3660.6591.6509.7484.3▲10.1%+10.7%
Cost of revenue
435.1413.0370.5347.0321.8297.3▲11.5%+8.6%
Gross profit
352.7314.3290.1244.6187.9187.1▲8.3%+13.9%
Research & development
39.337.131.227.330.321.9▲19.0%+14.1%
Selling, general & admin
259.9273.3259.7243.1243.4221.3▲5.2%+5.4%
Total operating expenses
402.0430.2382.2352.3345.5305.8▲12.6%+8.9%
Operating incomefeeds ROC rank
−49.4−115.9−92.1−107.7−157.6−118.8▼25.8%—
Other income, net
13.25.611.410.6−1.7103.7——
Pretax income
−36.2−110.3−80.7−97.1−159.3−15.1▼36.7%—
Income tax
−3.9−2.2−1.9−9.1−15.1−6.7▼15.1%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−32.3−108.0−78.7−88.0−144.3−8.3▼37.2%—
Per share
Diluted EPSbuyback-sensitive
−0.25−0.84−0.62−0.70−1.16—▼35.5%—
Diluted shares (mn)
128.59128.10126.66125.50124.22119.96▲1.1%+1.7%
Margins
Gross margin24th pct in Healthcare
44.8%43.2%43.9%41.3%36.9%38.6%▼0.7pp+4.6pp
Operating margin
−6.3%−15.9%−13.9%−18.2%−30.9%−24.5%▼2.0pp+8.6pp
Net margin33rd pct in Healthcare
−4.1%−14.9%−11.9%−14.9%−28.3%−1.7%▼2.9pp−13.1pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 45% vs a 9% norm for this window, likely a one-time item; see the filing.
FY10 – FY20 · 11 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 11 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Neogenomics' revenue last fiscal year?

Neogenomics reported revenue of $727.3M in fiscal 2025, up 10.1% from fiscal 2024.

What was Neogenomics' net income?

Neogenomics reported net income of −$108.0M in fiscal 2025, a net margin of −14.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.